Immunophenotypic characterization of human primary and metastatic melanoma infiltrating leukocytes

Anticancer Research

Volumn 16, Issue 6 B, 1996, Pages 3439-3446

  Bodey, Bela ^a,b   Bodey Jr , Bela ^a   Siegel, Stuart E ^b   Luck, James V ^c   Kaiser, Hans E ^d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c JOINT REPLACEMENT INSTITUTE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antigen presentation; CD antigens; CD8+ cytotoxic T lymphocytes; Granulocytes neutrophils; Immunocytochemistry; Immunophenotype; Leukocyte differentiation antigens; Macrophages; Metastatic melanoma; Monoclonal antibodies; Natural killer (NK) cells; Non specific anti tumor immune response; Primary melanoma; T lymphocytes; Tumor infiltrating leukocytes; Tumor specific immune reaction

Indexed keywords

ALKALINE PHOSPHATASE; ANTIGEN; DIFFERENTIATION ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOPHENOTYPING; INTERNALIZATION; LEUKOCYTE; MACROPHAGE; MELANOMA; METASTASIS; MONONUCLEAR CELL; MULTINUCLEAR CELL; NATURAL KILLER CELL; NEUTROPHIL; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; GRANULOCYTES; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LEUKOCYTES; MACROPHAGES; MELANOMA; T-LYMPHOCYTES;

EID: 0030508508     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Legha SS: Current therapy for malignant melanoma. Sem Oncol 16: 34-44, 1989.
2. Fountain IW, Bale SJ, Housman DE, Dracopoli NC: Genetics of Melanoma. Cancer Surveys 9: 645-671, 1990.
3. Clark WH, Jr, Elder DE, Guerry D, Epstein ME, Greene MH, van Horn M: A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Human Pathol 15: 1147-1165, 1984.
4. Poste G: Pathogenesis of metastatic disease: Implications for current therapy and for the development of new therapeutic strategies. Cancer Treat Rep 70: 183-198, 1986.
5. Duray PH, Palazzo J, Gown AM. Ohuchi N: Melanoma Cell Heterogeneity. Cancer 61: 2460-2468, 1988.
6. Guerry D, Synnestvedt M, Elder DE, Schultz D: Lessons from tumor progression. The invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol 100: S342-S345, 1993.
7. Herlyn M, Clark WH, Rodeck U, Mancianti ML, Jambrosic J, Koprowski H: Biology of tumor progression in human melanocytes. Lab Invest 56: 461-474, 1987.
8. Fearon ER, Vogelstein B: A genetic model for colorectal carcinogenesis. Cell 61: 759767, 1990.
9. Kerbel RS: Expression of multi-cytokine resistance and multigrowth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm. Am J Pathol 141: 519-524, 1992.
10. Lu C, Kerbel RS: Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 120: 1281-1288, 1993.
11. Weterman MAJ, van Muijen GNP, Bloemers HPJ, Ruiter DJ: Biology of Disease. Molecular markers of melanocytic tumor progression. Lab Invest 70: 593-608, 1994.
12. Chin Y, Janseens J, Vandepitte J, Vandenbrande J, Opdebeek L, Raus J: Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Res 12: 1463-1466, 1992.
13. Dietl J, Horny HP, Ruck P, Kaiserling E: Dysgerminoma of the ovary. An immunohistochemical study of tumor-infiltrating lymphoreti-cular cells and tumor cells. Cancer 71: 2562-2568, 1993.
14. Finke JH, Rayman P, Hart L, Alexander JP, Edinger MG, Tubbs RR, Klein E, Tuason L, Bokowski RM: Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity. interferon-gamma secretion, and proliferation. J Immunother Emph Tumor Immunol 15: 91-104, 1994.
15. + cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles. Int J Cancer 57: 56-62, 1994.
16. Bodey B, Bodey B, Jr, Siegel SE: Immunophenotypic characterization of infiltrating polynuclear and mononuclear cells in childhood brain tumors. Modern Pathol 8: 333-338, 1995.
17. Lanier LL, Phillips JH: Triggering structures on NK cells. In: Cytotoxic cells, Sitkovsky MV, Henkart PA (eds) Boston: Birkhauser, 1993, pp 84-95.
18. Townsend ARM, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ: The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 41: 959-968, 1986.
19. Townsend A, Bodmer H: Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 7: 601-624, 1989.
20. Elliott T, Townsend A, Cerundolo V: Naturally processed peptides. Nature 348: 195-197, 1990.
21. Old LJ: Cancer immunology: The search for specificity - G.H.A. Clowes Memorial Lecture, Cancer Res 41: 361-375, 1981.
22. Morton DL, Foshag LJ, Hoon DSB, Nize JA, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R, Irie RF: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Annals Surg 216: 463-482, 1992.
23. Cahan LD, Irie RF, Singh R, Cassidenti R, Paulson JC: Identification of a human neuroectodermal antigen (OFA-1-1) as ganglioside GD2. Proc Natl Acad Sci USA 79: 7629-7633, 1982.
24. Tai T, Paulson JC, Cahan CD, Irie RF: Ganglioside GM2 as a human tumor antigen (OFA-1-1). Proc Natl Acad Sci USA 80: 5392-5396. 1983.
25. M2 antibodies in melanoma patients. Proc Natl Acad Sci USA 84: 2911-2915, 1987.
26. Cheresh DA, Varki AP, Varki-NM, Stallcup WB, Levine J, Reisfield RA: A monoclonal antibody recognizes an O-acetyl sialic acid in a human melanoma-associated ganglioside. J Biol Chem 259: 7453-7459, 1984.
27. Ravindranath MH, Morton DL, Irie RF: An epitope common to gangliosides O-Acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res 49: 3891-3897, 1989.
28. Gupta RK, Morton DL: Studies of a melanoma tumor-associated antigen detected in the spent culture medium of a human melanoma cell line by allogeneic antibody: I. Purification and development of a radioimmunoassay. J Natl Cancer Inst 72: 67-74, 1984.
29. Gupta RK, Morton DL: Immunochemical characterization of fetal antigen isolated from spent medium of a human melanoma cell line. J Natl Cancer Inst 70: 993- 1003, 1983.
30. Euhus DM, Gupta RK.. Morton DL: Induction of antibodies to a tumor associated antigen by immunization with a whole melanoma cell vaccine. Cancer Immunol Immunother 29: 247-254, 1989.
31. Irie RF, Chandler PJ, Morton DT: Melanoma, gangliosides and human monoclonal antibody. In: Metzgar RS, Mitchell MS (eds) Human Tumor Antigens and Specific Tumor Therapy. New York: Alan R. Liss, 1989, pp 115-126.
32. Davis MM, Bjorkmann PJ: T-cell antigen receptor genes and T-cell recognition. Nature 334: 395-402, 1988.
33. Anichini A, Mazzocchi A, Fossati G, Parmiani G: Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction. J Immunol 142: 3692-3701, 1989.
34. Kourilsky P, Claverie J-M: MHC-antigen interaction: what does the T cell receptor see? Adv Immunol 45: 107-193, 1989.
35. Ando I, Hoon DSB, Suzuki Y, Golub SH, Irie RF: Ganglioside GM2 on the K562 cell line is recognized as a target structure by human natural killer cells. Int J Cancer 40: 12-17, 1987.
36. + human T cell clones isolated in IL-4. J Immunol 143: 452-457, 1989.
37. Parmiani G, Anichini A, Fossati G: Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy? J Natl Cancer Inst 82: 361-370, 1990.
38. Farmilo AJ, Stead RH: Fixation in immunocytochemistry. In: Handbook Immunochemical Staining Methods. Ed. Naish S.J., DAKO Corporation, 1989, pp. 24-29.
39. Shi S-R, Key ME, Kalra KL: Antigen retrieval in formalin fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39: 741-748, 1991.
40. Shi S-R, Cote C, Kalra K.L, Taylor CR, Tandon AK: A technique for retrieving antigens in formalin-fixed, routinely acid-decalcified, celloidin-embedded human temporal bone sections for immunohistochemistry. J Histochem Cytochem 40: 787-792, 1992.
41. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison of ABC and unlabeled antibody (PAP) procedure. J Histochem Cytochem 29: 577-581, 1981.
42. Janckila AJ, Yam LT, Li C-Y: Immunoalkaline phosphatase cytochemistry. Amer J Clin Pathol 84: 476-480, 1985.
43. Bodey B, Zeltzer PM, Saldivar V, Kemshead J: Immunophenotyping of childhood astrocytomas with a library of monoclonal antibodies. Int J Cancer 45: 1079-1087, 1990.
44. Versteeg R. Noordermeer IA, Kruese-Wolters M. Ruiter DJ, Schrier PI: c-myc down regulates class I HLA expression in human melanomas. EMBO J 7: 1023-1029, 1988.
45. Tanalca K, Yoshioka T, Bieberich C, Jay G: Role of the major histocompatibility complex class 1 antigen in tumor growth and metastasis. Annu Rev Immunol 6: 359-380, 1988.
46. Elliott BE, Carlow DA, Rodricks A-M, Wade A: Perspectives on the role of MHC antigens in normal and malignant cell development. Adv Cancer Res 53: 181-245, 1989.
47. Restifo NP, Esquivel F, Kawakami Y, Yewdell JM, Mule JJ, Rosenberg SA, Bennick JR: Identification of human cancers deficient in antigen processing. J Exp Med 177: 265-272, 1993.
48. Salgaller ML, Weber JS, Koenig S, Yannelli JR, Rosenberg SA: Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol Immunother 39: 105-116, 1994.
49. Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318-1321, 1986.
50. Schrier PI, Bernards R, Vaessen RTMJ, Houweling A, van der Eb AJ: Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells. Nature 305: 771-775, 1983.
51. Ljunggren H-G, Karre K: Host resistance directed selectively against H-2-deficient lymphoma variants: Analysis of the mechanism. J Exp Med 162: 1745-1759, 1985.
52. Karre K, Ljunggren H-G, Piontek G, Kiessling R: Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature 319: 675-678, 1986.
53. Litwin V, Gumperz J, Parham P, Lanier L: NKB-1: A natural killer receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med 180: 537-543, 1994.
54. Moretta A, Vitale M, Bottino C, Orengo AM, Morelli L, Augugliaro R, Barbaresi M, Ciccone E, Moretta L: P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-pS8 antibodies reconstitute lysis of MHC class I protected cells in NK clones displaying different specificities. J Exp Med 178: 597-604, 1993.
55. Welsh RM: Regulation of virus infections by natural killer cells: A review. Nat Immun Cell Growth Regul 5: 169-199, 1986.